周五盘中，Pacira Pharmaceuticals（PCRX）股价大幅下跌7.67%，延续了夜盘的跌势。这一显著跌幅主要源于公司最新发布的季度财报未能满足市场预期。
根据公司公布的财报，截至3月31日的季度调整后每股收益为62美分，略高于分析师平均预期的60美分。然而，公司营收同比仅增长1.1%，达到1.6892亿美元，低于分析师预期的1.7603亿美元。这一疲软的收入增长成为投资者关注的焦点，引发了市场对公司增长前景的担忧。
值得注意的是，近期分析师对Pacira Pharmaceuticals的盈利预期有所下调。过去三个月里，分析师的平均盈利预期下降了约23.2%。这些负面调整进一步加剧了投资者的担忧，推动了股价的持续下跌。尽管公司今年以来的股价表现较好，但这次业绩报告似乎未能满足市场的期望，导致股价出现大幅回调。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.